Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Genmab A/s LSE:0MGB London Ordinary Share DK0010272202 GENMAB ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  6.75 0.49% 1,381.50 1,351.50 1,411.50 1,381.50 1,381.50 1,381.50 7,533 08:00:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0

Genmab A/S Transactions With Shares And Linked Securities In Genmab A/S Made By Managerial Employees And Their Closely Associ...

26/03/2020 8:13pm

UK Regulatory (RNS & others)


 
TIDMGEN 
 
 
   Company Announcement 
 
   Copenhagen, Denmark; March 26, 2020 -- In accordance with Article 19 of 
Regulation No. 596/2014 on Market Abuse and Implementing Regulation 
2016/523, this document discloses the data of the transactions made in 
Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely 
associated persons. 
 
   The company's managerial employees and their closely associated persons 
have given Genmab A/S power of attorney on their behalf to publish 
trading in Genmab shares by the company's managerial employees and their 
closely associated persons. 
 
   About Genmab 
 
   Genmab is a publicly traded, international biotechnology company 
specializing in the creation and development of differentiated antibody 
therapeutics for the treatment of cancer. Founded in 1999, the company 
is the creator of three approved antibodies: DARZALEX(R) (daratumumab, 
under agreement with Janssen Biotech, Inc.) for the treatment of certain 
multiple myeloma indications in territories including the U.S., Europe 
and Japan, Arzerra(R) (ofatumumab, under agreement with Novartis AG), 
for the treatment of certain chronic lymphocytic leukemia indications in 
the U.S., Japan and certain other territories and TEPEZZA(TM) 
(teprotumumab, under agreement with Roche granting sublicense to Horizon 
Therapeutics plc) for the treatment of thyroid eye disease in the U.S. 
Daratumumab is in clinical development by Janssen for the treatment of 
additional multiple myeloma indications, other blood cancers and 
amyloidosis. A subcutaneous formulation of ofatumumab is in development 
by Novartis for the treatment of relapsing multiple sclerosis. Genmab 
also has a broad clinical and pre-clinical product pipeline. Genmab's 
technology base consists of validated and proprietary next generation 
antibody technologies - the DuoBody(R) platform for generation of 
bispecific antibodies, the HexaBody(R) platform, which creates effector 
function enhanced antibodies, the HexElect(R) platform, which combines 
two co-dependently acting HexaBody molecules to introduce selectivity 
while maximizing therapeutic potency and the DuoHexaBody(R) platform, 
which enhances the potential potency of bispecific antibodies through 
hexamerization. The company intends to leverage these technologies to 
create opportunities for full or co-ownership of future products. Genmab 
has alliances with top tier pharmaceutical and biotechnology companies. 
Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, 
the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. 
 
 
 
 
 
   Contact: 
 
   Marisol Peron, Corporate Vice President, Communications & Investor 
Relations 
 
   T: +1 609 524 0065; E: 
https://www.globenewswire.com/Tracker?data=BW76glvUEdHcheeJRWvjaDRDSEC4jKA11GsAh0KR9rsoH9IvgF8McP4ybZOVzvsI_4pdsOgKLB2YKTZY5c0QFQ== 
mmp@genmab.com 
 
   For Investor Relations: 
 
   Andrew Carlsen, Senior Director, Investor Relations 
 
   T: +45 3377 9558; E: 
https://www.globenewswire.com/Tracker?data=JvcenO38MioJfXtHLJHbJ8wrP9VzOtyE24RjxFd03XIbGTH07S59wGLSVUwAhZ3Vu2swLPpOMPRzbkdgLGPJiw== 
acn@genmab.com 
 
   This Company Announcement contains forward looking statements. The words 
"believe", "expect", "anticipate", "intend" and "plan" and similar 
expressions identify forward looking statements. Actual results or 
performance may differ materially from any future results or performance 
expressed or implied by such statements. The important factors that 
could cause our actual results or performance to differ materially 
include, among others, risks associated with pre-clinical and clinical 
development of products, uncertainties related to the outcome and 
conduct of clinical trials including unforeseen safety issues, 
uncertainties related to product manufacturing, the lack of market 
acceptance of our products, our inability to manage growth, the 
competitive environment in relation to our business area and markets, 
our inability to attract and retain suitably qualified personnel, the 
unenforceability or lack of protection of our patents and proprietary 
rights, our relationships with affiliated entities, changes and 
developments in technology which may render our products or technologies 
obsolete, and other factors. For a further discussion of these risks, 
please refer to the risk management sections in Genmab's most recent 
financial reports, which are available on 
https://www.globenewswire.com/Tracker?data=CFzZN3y38_JhMhl5EgMQzeC1WBij7veuQoTDE_B8tClQaS_eMzd4PO9V1X3QB0JY4DCB2kyJ3l1Bc5vPVL-r2w== 
www.genmab.com and the risk factors included in Genmab's final 
prospectus for our U.S. public offering and listing and other filings 
with the U.S. Securities and Exchange Commission (SEC), which are 
available at 
https://www.globenewswire.com/Tracker?data=CFzZN3y38_JhMhl5EgMQzRbiMydq6vkZ82rAwawKmglmkxkM-Pc2zm_4FljMXa-58wul4zZaVvr7Q916KfoBoLjcntOB1XTM2U5rNdFoT2c= 
www.sec.gov. Genmab does not undertake any obligation to update or 
revise forward looking statements in this Company Announcement nor to 
confirm such statements to reflect subsequent events or circumstances 
after the date made or in relation to actual results, unless required by 
law. 
 
   Genmab A/S and/or its subsidiaries own the following trademarks: 
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination with the 
Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody in combination 
with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in combination with 
the HexaBody logo(R) ; DuoHexaBody(R) ; HexElect(R) ; and UniBody(R) . 
Arzerra(R) is a trademark of Novartis AG or its affiliates. DARZALEX(R) 
is a trademark of Janssen Pharmaceutica NV. TEPEZZA(TM) is a trademark 
of Horizon Therapeutics plc. 
 
   CVR no. 2102 3884 
 
   LEI Code 529900MTJPDPE4MHJ122 
 
   Genmab A/S 
 
   Kalvebod Brygge 43 
 
   1560 Copenhagen V 
 
   Denmark 
 
   Attachment 
 
 
   -- 260320_CA14_Managerial Employee Transactions 
      https://ml-eu.globenewswire.com/Resource/Download/d829ec99-501a-4bf2-9948-47bf77f72bc1 
 
 
 
 
 
 
 

(END) Dow Jones Newswires

March 26, 2020 16:13 ET (20:13 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year Genmab A/s Chart

1 Year Genmab A/s Chart

1 Month Genmab A/s Chart

1 Month Genmab A/s Chart
ADVFN Advertorial
Your Recent History
LSE
0MGB
Genmab A/s
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200403 18:36:03